
CVS stock rallies as health giant signals stronger-than-expected results in 2025

I'm PortAI, I can summarize articles.
CVS Health has raised its 2025 revenue guidance to $400 billion, surpassing previous estimates and FactSet's forecast. The company also increased its adjusted EPS guidance to $6.60-$6.70. CVS attributes its strong performance to Aetna's target margins and growth in its pharmacy-benefit business. CVS stock has risen 78% this year, outperforming other health insurers. The company expects 2026 revenue of $400 billion and adjusted EPS of $7-$7.20.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.

